Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K8 | P41279 | 3/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | CYTH3 | O43739 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18367757 | 0.83 | MAP3K8 (0.49) | MAP3K8KMT2AMAPTMEN1ALDH1A1 | |
| SCHEMBL18367763 | 0.82 | MAP3K8 (0.39) | MAP3K8KMT2AMAPTMEN1HTT | |
| SCHEMBL18367764 | 0.79 | EGFR (0.54) | — | |
| SCHEMBL28499725 | 0.79 | EGFR (0.54) | — | |
| SCHEMBL29352935 | 0.78 | EGFR (0.57) | — | |
| SCHEMBL28508007 | 0.78 | EGFR (0.57) | — | |
| SCHEMBL18367766 | 0.78 | EGFR (0.57) | — | |
| SCHEMBL18367745 | 0.77 | EGFR (0.56) | — | |
| SCHEMBL29350152 | 0.77 | EGFR (0.56) | — | |
| SCHEMBL28506120 | 0.77 | EGFR (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108026067-B | 6-amino-quinoline-3-carbonitriles as COT modulators | 吉利德科学公司 | 2021-01-12 | — | — | CN | disclosed |
| EP-3319955-B1 | 6-AMINO-QUINOLINE-3-CARBONITRILS AS COT MODULATORS | GILEAD SCIENCES INC (US) | 2020-11-25 | — | — | EP | disclosed |
| US-10316017-B2 | COT modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| EP-3319955-A1 | 6-AMINO-QUINOLINE-3-CARBONITRILS AS COT MODULATORS | Gilead Sciences, Inc. (US) | 2018-05-16 | — | — | EP | disclosed |
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9815818-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815818-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815818-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170008873-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
| WO-2017007694-A1 | 6-AMINO-QUINOLINE-3-CARBONITRILS AS COT MODULATORS | GILEAD SCIENCES, INC. (US) | 2017-01-12 | — | — | WO | disclosed |
| US-20170008873-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
| WO-2017007694-A1 | 6-AMINO-QUINOLINE-3-CARBONITRILS AS COT MODULATORS | GILEAD SCIENCES, INC. (US) | 2017-01-12 | — | — | WO | disclosed |
| US-20170008873-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | MAP3K8 2359/4885PDPK1 1646/4885CYTH3 73/4885 |
| US-10316017-B2 | COT modulators and methods of use thereof | BRDT, THRB, HCCS | MAP3K8 2359/4885PDPK1 1646/4885CYTH3 73/4885 |
| US-20170008873-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | MAP3K8 2359/4885PDPK1 1646/4885CYTH3 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.